Literature DB >> 25963524

ARID1A and TERT promoter mutations in dedifferentiated meningioma.

Malak S Abedalthagafi1, Wenya Linda Bi2, Parker H Merrill1, William J Gibson3, Matthew F Rose1, Ziming Du1, Joshua M Francis4, Rose Du2, Ian F Dunn2, Azra H Ligon5, Rameen Beroukhim6, Sandro Santagata7.   

Abstract

Unlike patients with World Health Organization (WHO) grade I meningiomas, which are considered benign, patients with WHO grade III meningiomas have very high mortality rates. The principles underlying tumor progression in meningioma are largely unknown, yet a detailed understanding of these mechanisms will be required for effective management of patients with these high grade lethal tumors. We present a case of an intraventricular meningioma that at first presentation displayed remarkable morphologic heterogeneity-composed of distinct regions independently fulfilling histopathologic criteria for WHO grade I, II, and III designations. The lowest grade regions had classic meningothelial features, while the highest grade regions were markedly dedifferentiated. Whereas progression in meningiomas is generally observed during recurrence following radiation and systemic medical therapies, the current case offers us a snapshot of histologic progression and intratumoral heterogeneity in a native pretreatment context. Using whole exome sequencing and high resolution array-based comparative genomic hybridization, we observed marked genetic heterogeneity between the various areas. Notably, in the higher grade regions we found increased aneuploidy with progressive loss of heterozygosity, the emergence of mutations in the TERT promoter, and compromise of ARID1A. These findings provide new insights into intratumoral heterogeneity in the evolution of malignant phenotypes in anaplastic meningiomas and potential pathways of malignant progression.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Meningioma; SWI/SNF complex; anaplastic; chromatin remodeling; intratumoral heterogeneity

Mesh:

Substances:

Year:  2015        PMID: 25963524      PMCID: PMC4882906          DOI: 10.1016/j.cancergen.2015.03.005

Source DB:  PubMed          Journal:  Cancer Genet


  30 in total

1.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

2.  Simultaneous genotype calling and haplotype phasing improves genotype accuracy and reduces false-positive associations for genome-wide association studies.

Authors:  Brian L Browning; Zhaoxia Yu
Journal:  Am J Hum Genet       Date:  2009-12       Impact factor: 11.025

3.  Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.

Authors:  J Boström; B Meyer-Puttlitz; M Wolter; B Blaschke; R G Weber; P Lichter; K Ichimura; V P Collins; G Reifenberger
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

Review 4.  The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.

Authors:  Winward Choy; Won Kim; Daniel Nagasawa; Stephanie Stramotas; Andrew Yew; Quinton Gopen; Andrew T Parsa; Isaac Yang
Journal:  Neurosurg Focus       Date:  2011-05       Impact factor: 4.047

5.  AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.

Authors:  Felix Sahm; Juliane Bissel; Christian Koelsche; Leonille Schweizer; David Capper; David Reuss; Katja Böhmer; Ulrike Lass; Tanja Göck; Katrin Kalis; Jochen Meyer; Antje Habel; Stefanie Brehmer; Michel Mittelbronn; David T W Jones; Jens Schittenhelm; Steffi Urbschat; Ralf Ketter; Stephanie Heim; Christian Mawrin; Johannes A Hainfellner; Anna-Sophie Berghoff; Matthias Preusser; Albert Becker; Christel Herold-Mende; Andreas Unterberg; Christian Hartmann; Philipp Kickingereder; V Peter Collins; Stefan M Pfister; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2013-10-06       Impact factor: 17.088

6.  Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.

Authors:  David E Reuss; Rosario M Piro; David T W Jones; Matthias Simon; Ralf Ketter; Marcel Kool; Albert Becker; Felix Sahm; Stefan Pusch; Jochen Meyer; Christian Hagenlocher; Leonille Schweizer; David Capper; Phillipp Kickingereder; Jana Mucha; Christian Koelsche; Natalie Jäger; Thomas Santarius; Patrick S Tarpey; Philip J Stephens; P Andrew Futreal; Ruth Wellenreuther; Jürgen Kraus; Doris Lenartz; Christel Herold-Mende; Christian Hartmann; Christian Mawrin; Nathalia Giese; Roland Eils; V Peter Collins; Rainer König; Otmar D Wiestler; Stefan M Pfister; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2013-02-12       Impact factor: 17.088

7.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

Authors:  Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

8.  DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues.

Authors:  Justin M Craig; Natalie Vena; Shakti Ramkissoon; Ahmed Idbaih; Shaun D Fouse; Memet Ozek; Aydin Sav; D Ashley Hill; Linda R Margraf; Charles G Eberhart; Mark W Kieran; Andrew D Norden; Patrick Y Wen; Massimo Loda; Sandro Santagata; Keith L Ligon; Azra H Ligon
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

9.  Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.

Authors:  Ziming Du; Malak Abedalthagafi; Ayal A Aizer; Allison R McHenry; Heather H Sun; Mark-Anthony Bray; Omar Viramontes; Revaz Machaidze; Priscilla K Brastianos; David A Reardon; Ian F Dunn; Gordon J Freeman; Keith L Ligon; Anne E Carpenter; Brian M Alexander; Nathalie Y Agar; Scott J Rodig; Elizabeth M Bradshaw; Sandro Santagata
Journal:  Oncotarget       Date:  2015-03-10

10.  Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.

Authors:  Priscilla K Brastianos; Amaro Taylor-Weiner; Peter E Manley; Robert T Jones; Dora Dias-Santagata; Aaron R Thorner; Michael S Lawrence; Fausto J Rodriguez; Lindsay A Bernardo; Laura Schubert; Ashwini Sunkavalli; Nick Shillingford; Monica L Calicchio; Hart G W Lidov; Hala Taha; Maria Martinez-Lage; Mariarita Santi; Phillip B Storm; John Y K Lee; James N Palmer; Nithin D Adappa; R Michael Scott; Ian F Dunn; Edward R Laws; Chip Stewart; Keith L Ligon; Mai P Hoang; Paul Van Hummelen; William C Hahn; David N Louis; Adam C Resnick; Mark W Kieran; Gad Getz; Sandro Santagata
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 38.330

View more
  31 in total

1.  The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.

Authors:  Victor M Lu; Anshit Goyal; Adrian Lee; Mark Jentoft; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana
Journal:  J Neurooncol       Date:  2018-12-01       Impact factor: 4.130

2.  TERT, the target?

Authors:  Felix Sahm; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 12.300

3.  SWI/SNF complex-deficient soft tissue neoplasms: An update.

Authors:  Inga-Marie Schaefer; Jason L Hornick
Journal:  Semin Diagn Pathol       Date:  2020-06-05       Impact factor: 3.464

4.  SWI/SNF chromatin remodeling complex alterations in meningioma.

Authors:  Corey M Gill; Joshua Loewenstern; John W Rutland; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Mary Fowkes; Raj K Shrivastava
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-14       Impact factor: 4.553

Review 5.  Diagnostic challenges in meningioma.

Authors:  Martha Nowosielski; Norbert Galldiks; Sarah Iglseder; Philipp Kickingereder; Andreas von Deimling; Martin Bendszus; Wolfgang Wick; Felix Sahm
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

Review 6.  BAP1 mutations in high-grade meningioma: implications for patient care.

Authors:  Ganesh M Shankar; Sandro Santagata
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

7.  WHO grade of intracranial meningiomas differs with respect to patient's age, location, tumor size and peritumoral edema.

Authors:  Anne Ressel; Susanne Fichte; Michael Brodhun; Steffen K Rosahl; Ruediger Gerlach
Journal:  J Neurooncol       Date:  2019-10-01       Impact factor: 4.130

8.  Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours.

Authors:  Malak S Abedalthagafi; Michael P Wu; Parker H Merrill; Ziming Du; Terri Woo; Shu-Hsien Sheu; Shelley Hurwitz; Keith L Ligon; Sandro Santagata
Journal:  J Pathol       Date:  2016-03       Impact factor: 7.996

9.  Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma.

Authors:  Dustin T Proctor; Zeel Patel; Sanju Lama; Lothar Resch; Guido van Marle; Garnette R Sutherland
Journal:  Oncoimmunology       Date:  2018-09-05       Impact factor: 8.110

10.  De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.

Authors:  Matthieu Peyre; Guillaume Gauchotte; Marine Giry; Sébastien Froehlich; Johan Pallud; Thomas Graillon; Franck Bielle; Dominique Cazals-Hatem; Pascale Varlet; Dominique Figarella-Branger; Hugues Loiseau; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.